← 홈

고형암 (전체)

911개 · ADC 1068 · Antibody 5456 · CGT 2744 · 다음 갱신 D-13 · 마지막 7월 13일

인기최근 업데이트큐레이션임상 많은갱신 필요ORR최신Phase 3FDA승인프로그램 911개
ADCBHotBiologicDaiichi SankyoPhase 1

DP (DS-8201a, DS-8201a (DP))

Advanced Solid Tumors · Advanced Solid Tumors

#AdvancedSolidTumors#ADC#Phase1#인기#항체약물접합체+2
효능 ORR 69.7%임상시험 107상태 ACTIVE
ADCSHotBiologicRocheDM1 via butelase-1 with ABD…Approved

trastuzumab (Herceptin, Trastuzumab Emtansine)

HER2 Mutant Non-small Cell Lung Cancer; HER2-positive Metastatic Breast Cancer · Metastatic Salivary Gland Carcinoma

#MetastaticSalivaryGlandCarcinoma#ADC#Approved#인기#항체약물접합체+5
효능 ORR 69.7%임상시험 106상태 RECRUITING
ADCBHotBiologicK-Group, Beta, Inc., a wholly o…atPhase 3

Gemcitabine Hydrochloride (Gemcitabine Hydrochloride)

Clear Cell Adenocarcinoma; Fallopian Tube Clear Cell Adenocarcinoma · FRα

#FR#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 50%임상시험 105상태 RECRUITING
ADCBHotBiologicPharmacyclics LLC.Phase 3

Ibrutinib (Ibrutinib)

Metastatic Renal Cell Carcinoma; Advanced Urothelial Carcinoma · Non-Hodgkin Lymphoma

#Non-HodgkinLymphoma#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 93.9%임상시험 105상태 ACTIVE
AntibodyBHotBeiGeneVedotin, Tislelizumab, and …Phase 1

BGB-A317 (Tislelizumab, Tislelizumab (BGB-A317))

Advanced Solid Tumor · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase1#인기#항체+5
효능 ORR 68.3%임상시험 105상태 RECRUITING
ADCBHotBiologicNovartis PharmaceuticalsApproved

Prednisolone (Prednisolone)

Healthy · Solid Tumor

#SolidTumor#ADC#Approved#인기#항체약물접합체+3
효능 ORR 47%임상시험 102상태 RECRUITING
AntibodyCHotRochederuxtecan plus fluoropyrim…Phase 2

trastuzumab (Herceptin, FLOT, 5-FU, leucovorin, docetaxel, oxaliplatin, 5-FU, leucovorin, docetaxel, oxaliplatin (FLOT), trastuzumab)

Adenocarcinoma of the Gastroesophageal Junction; Adenocarcinoma of the Stomach · Adenocarcinoma of the Gastroesophageal J

#AdenocarcinomaoftheGastroesophag#Antibody#Phase2#인기#항체+5
효능 ORR 61%임상시험 100상태 ACTIVE
ADCCBiologicEMD SeronoSN-38 for the treatment of …Phase 2

TMZ (Temozolomide, Temozolomide (TMZ))

Childhood Cancer; Childhood Solid Tumor · Advanced Solid Malignancies

#AdvancedSolidMalignancies#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 40%임상시험 97상태 RECRUITING
AntibodyCBeiGeneVedotin, Tislelizumab, and …Phase 2

Tislelizumab (Tislelizumab)

Locally Recurrent Colorectal Cancer · Advanced Solid Tumor

#AdvancedSolidTumor#Antibody#Phase2#인기#항체+5
효능 ORR 37.1%임상시험 96상태 RECRUITING
AntibodyCInnoventvedotin (an HER2-targeted a…Phase 3

Sintilimab (Sintilimab)

Advanced Hepatocellular Carcinoma (HCC) · HER2

#HER2#Antibody#Phase3#인기#항체+5
임상시험 95상태 RECRUITING
ADCCBiologicJiangsu Simcere Pharmaceutical …Phase 3

Palbociclib (Palbociclib)

Head and Neck Squamous Cell Carcinoma · FRα

#FR#ADC#Phase3#인기#항체약물접합체+3
효능 ORR 79.5%임상시험 92상태 DISCONTINUED
ADCABiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 2

trastuzumab deruxtecan (Enhertu, T-DXd, DS-8201, Trastuzumab Deruxtecan (T-DXd) monotherapy)

Gastric Adenocarcinoma; Gastroesophageal Junction Adenocarcinoma · Gastric Adenocarcinoma

#GastricAdenocarcinoma#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 79.7%임상시험 91상태 RECRUITING
ADCCBiologicAcademic and Community Cancer R…Phase 2

Cabozantinib (Cabozantinib)

Locally Advanced Hepatocellular Carcinoma; Metastatic Hepatocellular Carcinoma · FRα

#FR#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 59%임상시험 89상태 DISCONTINUED
AntibodyARochePhase 3

atezolizumab (Tecentriq, MPDL3280A, Atezolizumab (MPDL3280A), an engineered anti-PD-L1 antibody)

Carcinoma, Non-Squamous Non-Small Cell Lung · PD-L1

#PD-L1#Antibody#Phase3#인기#항체+5
효능 ORR 76.7%임상시험 88상태 ACTIVE
ADCABiologicJanssen Research & Development,…Phase 3

Osimertinib (Osimertinib)

Carcinoma, Non-Small-Cell Lung · FRα

#FR#ADC#Phase3#인기#항체약물접합체+4
효능 ORR 76.7%임상시험 88상태 RECRUITING
AntibodyCEli Lilly and CompanyDeruxtecan]Phase 3

Ramucirumab (Ramucirumab)

Advanced Esophageal Adenocarcinoma; Advanced Gastric Adenocarcinoma · Non-Small Cell Lung Cancer

#Non-SmallCellLungCancer#Antibody#Phase3#인기#항체+5
효능 ORR 40%임상시험 86상태 RECRUITING
AntibodyCRegeneronPhase 2

Cemiplimab (Cemiplimab)

Breast Neoplasms; Breast Cancer · Solid Tumor

#SolidTumor#Antibody#Phase2#인기#항체+5
효능 ORR 44%임상시험 84상태 RECRUITING
ADCSBiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 3

DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (DS-8201a))

Breast Cancer; Non-small Cell Lung Carcinoma · Breast Cancer

#BreastCancer#ADC#Phase3#인기#항체약물접합체+5
효능 ORR 79.7%임상시험 84상태 RECRUITING
ADCABiologicDaiichi Sankyoderuxtecan (Dato-DXd, Datro…Phase 2

T-DXd, DS-8201a (Trastuzumab deruxtecan, Trastuzumab deruxtecan (T-DXd, DS-8201a))

Advanced Breast Cancer; Advanced Breast Carcinoma · Advanced Breast Cancer

#AdvancedBreastCancer#ADC#Phase2#인기#항체약물접합체+5
효능 ORR 79.7%임상시험 84상태 RECRUITING
AntibodyAAmgenPhase 3

Panitumumab (Panitumumab)

Colorectal Cancer; Resectable Colorectal Carcinoma · Head and Neck Squamous Cell Carcinoma

#HeadandNeckSquamousCellCarcinoma#Antibody#Phase3#인기#항체+5
효능 ORR 77.3%임상시험 83상태 RECRUITING

2 / 46 페이지

← 이전다음 →